Competition heats up for extended VTE market
This article was originally published in Scrip
Executive Summary
With more new anticoagulant agents poised to join current therapy options for the extended treatment of venous thromboembolism (VTE), there are calls for better ways of identifying those patients at greatest risk of recurrent VTE events since they stand to benefit most from such treatments.